Inhibrx Biosciences director awarded stock options

Inhibrx Biosciences, Inc. director Jon Faiz Kayyem received a grant of stock options covering 15,000 shares of common stock.

The filer has since corrected this document, so the figures below are the ones originally reported and some of them may have changed. Read the amended Form 4/A for what the company says now.

Rhea-AI Filing Summary

Inhibrx Biosciences, Inc. director Jon Faiz Kayyem received a grant of stock options covering 15,000 shares of common stock. The options have an exercise price of $95.2200 per share and become fully exercisable on June 3, 2027, subject to his continued service.

The options expire on June 3, 2036. Following this award, Kayyem holds 15,000 derivative securities (stock options) directly. This is a compensation-related grant, not an open‑market purchase or sale of shares.

Insights

Equity compensation analyst

Routine director stock option grant with long-term vesting.

Director Jon Faiz Kayyem received stock options for 15,000 shares of Inhibrx Biosciences common stock at an exercise price of $95.2200. The transaction is coded as a grant, indicating compensation rather than an open-market trade.

The options vest in full on June 3, 2027, contingent on continued service, and expire on June 3, 2036. Because this is a standard equity award with no immediate share sale or purchase, it typically carries limited signaling value about the director’s view of the stock.

Insider Trade Summary

Grant/Award: 15,000 shares

Grant/Award 1 txn

Insider Kayyem Jon Faiz

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	15,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 15,000 contracts (Direct)

Footnotes (1)

1. F1. This stock option will be fully exercisable on June 3, 2027, subject to the reporting person's continued service through such date.

Key Figures

Stock options granted: 15,000 options Exercise price: $95.2200 per share Underlying shares: 15,000 shares +3 more

6 metrics

Stock options granted 15,000 options Grant to director on June 3, 2026

Exercise price $95.2200 per share Strike price of granted options

Underlying shares 15,000 shares Common stock underlying the options

Vesting date June 3, 2027 Date options become fully exercisable

Expiration date June 3, 2036 Options term end

Options held after grant 15,000 options Total derivative securities following transaction

Key Terms

Stock Option (right to buy), Grant, award, or other acquisition, exercise price, fully exercisable

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

exercise price financial

"conversion_or_exercise_price: 95.2200"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

fully exercisable financial

"This stock option will be fully exercisable on June 3, 2027"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Inhibrx Biosciences (INBX) director Jon Faiz Kayyem report on this Form 4?

He reported receiving a stock option grant for 15,000 shares of common stock. The options are a compensation-related award, not a market trade, and give him the right to buy shares at a fixed exercise price in the future.

How many Inhibrx Biosciences (INBX) shares are covered by the new stock options?

The grant covers options on 15,000 shares of Inhibrx Biosciences common stock. These options, if exercised in the future, would allow the director to purchase that number of shares at the predetermined exercise price stated in the filing.

What is the exercise price and vesting date of Jon Faiz Kayyem’s INBX stock options?

The options have an exercise price of $95.2200 per share and become fully exercisable on June 3, 2027. Vesting is conditioned on Kayyem’s continued service with the company through that vesting date, as noted in the footnote.

When do the newly granted Inhibrx Biosciences (INBX) stock options expire?

The stock options expire on June 3, 2036, giving a 10-year term from the grant date. After this expiration date, any unexercised options will lapse and no longer provide the right to purchase Inhibrx Biosciences common shares.

Is this INBX Form 4 an open-market buy or sell by the director?

No, this Form 4 reports a grant of stock options as compensation rather than an open-market purchase or sale. The director acquires derivative rights, not common shares, and there is no immediate cash transaction in the market for INBX stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/04/2026 - 05:29 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kayyem Jon Faiz

(Last) (First) (Middle)

C/O INHIBRX BIOSCIENCES, INC.

11025 NORTH TORREY PINES ROAD, SUITE 140

(Street)

LA JOLLA CALIFORNIA 92037

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Inhibrx Biosciences, Inc. [ INBX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$95.22	06/03/2026		A		15,000		06/03/2027(1)	06/03/2036	Common Stock	15,000	$0	15,000	D

Explanation of Responses:

1. This stock option will be fully exercisable on June 3, 2027, subject to the reporting person's continued service through such date.

Remarks:

	/s/ Kelly Deck, as attorney-in-fact to Jon Faiz Kayyem	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)